Tyler Green, MD
Internal Medicine · Huntsville, ALNPI 1417390543
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 405 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 37 manufacturers reported payments, led by Novo Nordisk at 27.6% of the total.
Across 405 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Lilly USA, LLC$541
- GSK$406
- Johnson & Johnson$263
- Astellas Pharma US Inc$247
- plus $2K from 31 others
What the payments were for
- Food & beverage$6,500100%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 155 | $1,803 |
| AstraZeneca | 55 | $1,020 |
| Lilly USA, LLC | 41 | $541 |
| GSK | 21 | $406 |
| Johnson & Johnson | 10 | $263 |
| Astellas Pharma US Inc | 11 | $247 |
| Boehringer Ingelheim | 7 | $232 |
| AbbVie(2 entities) | 14 | $221 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $147 |
| Abbott | 7 | $138 |
| Exact Sciences | 7 | $136 |
| Amgen | 6 | $130 |
| Corcept Therapeutics | 5 | $125 |
| Sumitomo Pharma America, Inc. | 6 | $115 |
| Pfizer | 7 | $114 |
| Inari Medical, Inc. | 1 | $100 |
| Shield Therapeutics Inc | 5 | $91 |
| Daiichi Sankyo Inc. | 5 | $85 |
| Kowa Pharmaceuticals America, Inc. | 5 | $79 |
| Sanofi Pasteur Inc. | 4 | $71 |
| Bayer | 3 | $66 |
| Esperion Therapeutics, Inc. | 3 | $54 |
| Philips North America LLC | 3 | $49 |
| Dexcom, Inc. | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Merck | 2 | $29 |
| Intra-sana Laboratories | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $24 |
| Medtronic | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Corium, LLC | 1 | $18 |
| Novartis | 1 | $16 |
| Insulet Corporation | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $13 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$125
- JARDIANCE$122
- Ozempic$109
- FLOWTRIEVER CATHETER, S$100
- CT THROMBECTOMY SYSTEM KIT$100
How this compares
$6,532 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 224 | $339,075 |
| JardianceEmpagliflozin | 79 | $98,211 |
| EliquisApixaban | 95 | $93,029 |
| MounjaroTirzepatide | 61 | $85,783 |
| RybelsusSemaglutide | 22 | $49,733 |
| FarxigaDapagliflozin Propanediol | 62 | $47,445 |
| XareltoRivaroxaban | 32 | $34,602 |
| MyrbetriqMirabegron | 31 | $27,590 |
| JanuviaSitagliptin Phosphate | 22 | $26,922 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 24 | $22,699 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $18,992 |
| LivaloPitavastatin Calcium | 13 | $12,570 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $11,987 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $10,478 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 26 | $10,106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,803 | $388,808246 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $232 | $104,86990 claims |
| PfizerEliquis | $114 | $93,02995 claims |
| Lilly USA, LLCMounjaro | $541 | $85,78361 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,020 | $80,622128 claims |
| Johnson & JohnsonXarelto | $263 | $34,60232 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $406 | $30,97947 claims |
| Astellas Pharma US IncMyrbetriq | $247 | $27,59031 claims |
| MerckJanuvia | $29 | $26,92222 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $79 | $12,57013 claims |
| AbbVieSynthroid | $221 | $4,51554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Huntsville
- Joseph HastieHuntsville$44K
- Vytautas PukisHuntsville$16K
- Tanja DudenbostelHuntsville$14K
- Ryan WeldonBirmingham$458K
- Thomas McKelveyMobile$365K
- Mary HonkanenMobile$302K
- Robert LewisBirmingham$187K
- Rosalind BowlesGadsden$168K
- Sonja PettusJasper$117K
- Bobby WrightsMobile$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.